Literature DB >> 18156937

Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital.

Mehrdad Nikfarjam1, Andrew L Warshaw, Lloyd Axelrod, Vikram Deshpande, Sarah P Thayer, Cristina R Ferrone, Carlos Fernández-del Castillo.   

Abstract

OBJECTIVE: To determine changes in the management strategy of patients with insulinomas and identify critical factors in patient outcome.
BACKGROUND: Pancreatic insulinomas are rare neoplasms that are present in various ways. The optimal approach to localization, operative management, and follow-up of insulinomas is undetermined.
METHODS: Sixty-one patients with a diagnosis of insulinoma requiring surgery at a tertiary care center between 1983 and 2007 were reviewed. Demographic details, mode of presentation, preoperative localization, operative procedures, and pathology data were assessed. The effect of different factors on survival was determined.
RESULTS: Seven of 61 (11%) patients had a diagnosis of multiple endocrine neoplasia-type 1 (MEN-1). Multiple insulinomas were noted in 8% of cases and were more common in MEN-1 patients. The overall rate of malignancy was 8%. Confusion (67%), visual disturbances (42%), and diaphoresis (30%) were the most common presenting symptoms. Weight gain was noted in 44% of patients. The median duration of symptoms before diagnosis was 18 (1-240) months. The sensitivity of preoperative imaging of tumors before 1994 was 75%, compared with 98% after this period, which included use of endoscopic ultrasound scanning (P = 0.012). A combination of palpation and intraoperative ultrasound detected 92% of tumors. Distal pancreatectomy (40%), enucleation (34%), and pancreaticoduodenectomy (16%) were the most common procedures and pancreatic fistula occurred in 18% of patients. Three patients underwent noncurative distal pancreatectomy in the early period. The 10-year disease-specific and disease-free survival was 100% and 90% respectively. There were 5 patients with disease recurrence. Lymph node metastases (P < 0.001), lymphovascular invasion (P < 0.001), and the presence of MEN-1 (P = 0.035) were prognostically significant adverse factors in disease-free survival. Lymphovascular invasion was the only significant factor on multivariate analysis (P = 0.002).
CONCLUSION: Pancreatic insulinomas can be readily localized preoperatively with modern imaging to avoid unsuccessful blind pancreatic resection. Surgical resection is associated with low morbidity and mortality and achieves long-term disease-free survival in the absence of lymphovascular invasion.

Entities:  

Mesh:

Year:  2008        PMID: 18156937      PMCID: PMC3806046          DOI: 10.1097/SLA.0b013e31815792ed

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  37 in total

1.  What preoperative assessment is necessary for insulinomas? Calculating the degree of waste: analysis of 29 cases.

Authors:  Massimo Falconi; Enrico Molinari; Giovanni Carbognin; Giuseppe Zamboni; Claudio Bassi; Paolo Pederzoli
Journal:  Chir Ital       Date:  2002 Sep-Oct

Review 2.  Insulinoma.

Authors:  Clive S Grant
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-10       Impact factor: 3.043

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization.

Authors:  J H Balcom; D W Rattner; A L Warshaw; Y Chang; C Fernandez-del Castillo
Journal:  Arch Surg       Date:  2001-04

5.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas.

Authors:  M A Anderson; S Carpenter; N W Thompson; T T Nostrant; G H Elta; J M Scheiman
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

6.  Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

Authors:  Jeffrey A Norton; Maryann Kivlen; Michelle Li; Darren Schneider; Timothy Chuter; Robert T Jensen
Journal:  Arch Surg       Date:  2003-08

7.  Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity.

Authors:  J Shawn Mallery; Barbara A Centeno; Peter F Hahn; YuChiao Chang; Andrew L Warshaw; William R Brugge
Journal:  Gastrointest Endosc       Date:  2002-08       Impact factor: 9.427

Review 8.  Surgical treatment of insulinomas.

Authors:  Emily Finlayson; Orlo H Clark
Journal:  Surg Clin North Am       Date:  2004-06       Impact factor: 2.741

9.  Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure.

Authors:  Boaz Hirshberg; Steven K Libutti; H Richard Alexander; David L Bartlett; Craig Cochran; Andrea Livi; Richard Chang; Thomas Shawker; Monica C Skarulis; Phillip Gorden
Journal:  J Am Coll Surg       Date:  2002-06       Impact factor: 6.113

Review 10.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

View more
  62 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

3.  Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.

Authors:  David J Worhunsky; Geoffrey W Krampitz; Peter D Poullos; Brendan C Visser; Pamela L Kunz; George A Fisher; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

4.  Open and minimally invasive pancreatic neoplasms enucleation: a systematic review.

Authors:  Raffaele Dalla Valle; Elena Cremaschi; Laura Lamecchi; Francesca Guerini; Edoardo Rosso; Maurizio Iaria
Journal:  Surg Endosc       Date:  2019-07-30       Impact factor: 4.584

Review 5.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

6.  Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors.

Authors:  Kristin Heeger; Massimo Falconi; Stefano Partelli; Jens Waldmann; Stefano Crippa; Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2014-02-14       Impact factor: 3.445

7.  Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years.

Authors:  Brian K P Goh; London L P J Ooi; Peng-Chung Cheow; Yu-Meng Tan; Hock-Soo Ong; Yaw-Fui A Chung; Pierce K H Chow; Wai-Keong Wong; Khee-Chee Soo
Journal:  J Gastrointest Surg       Date:  2009-03-17       Impact factor: 3.452

Review 8.  The treatment of hyperinsulinemic hypoglycaemia in adults: an update.

Authors:  M V Davi; A Pia; V Guarnotta; G Pizza; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2016-09-13       Impact factor: 4.256

Review 9.  Insulinoma.

Authors:  Aarti Mathur; Philip Gorden; Steven K Libutti
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

Review 10.  Neuroendocrine tumors of the pancreas.

Authors:  Karen Davies; Kevin C Conlon
Journal:  Curr Gastroenterol Rep       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.